Lantern Pharma will broaden access to its RADR® AI platform via a freemium model to drive collaboration and growth. CEO Panna Sharma called Q1 2025 a “pivotal inflection point,” citing clinical portfolio advances and RADR® expansion to over 200 billion oncology-focused data points.
